• Strategy
  • Payers
  • AI
  • Cybersecurity
  • Device Development
  • Studies/Published Research
  • Ethics
  • Regulatory
  • Digital Biomarkers
  • Data Science
  • Companion Diagnostics
  • Clinical Care
  • Digital Therapeutics
  • Academic Research
  • Virtual Reality
  • RWE
  • Digital Endpoints
  • Medical Devices (Class II and Class III)
  • Commercialization
  • Clinical Trials
  • Drug-Device Combinations
  • SaMD
  • Remote Patient Monitoring
  • Patient Engagement
  • Profiles/Q&A

DiMe and Partners Align on Digital Atopic Dermatitis Endpoint

Article

The Digital Medicine Society (DiMe) releases new set of resources to advance the use of digitally measured nocturnal scratch as a meaningful endpoint for atopic dermatitis (AD).

DiMe's release of a new set of resources to advance the use of digitally measured nocturnal scratch as a meaningful endpoint for atopic dermatitis (AD) was completed with founding project partners AbbVie, the Janssen Pharmaceutical Companies of Johnson & Johnson, Novartis, Pfizer, and UCB, along with project collaborators Advancing Innovation in Dermatology, Almirall, Eli Lilly, GSK, Leo Pharma, and Sanofi. In just nine months, the collaboration conducted a mixed-methods study, a comprehensive literature review, a series of workshops, a series of focus groups with payers, and convened a meeting with regulators - all of which informed the development of these open-access resources.

Read the full press release.

© 2024 MJH Life Sciences

All rights reserved.